657 related articles for article (PubMed ID: 26492594)
1. Bortezomib for refractory acute antibody-mediated rejection in kidney transplant recipients: A single-centre case series.
De Sousa-Amorim E; Revuelta I; Diekmann F; Cofan F; Lozano M; Cid J; Palou E; Sole M; Campistol JM; Oppenheimer F
Nephrology (Carlton); 2016 Aug; 21(8):700-4. PubMed ID: 26492594
[TBL] [Abstract][Full Text] [Related]
2. Bortezomib in late antibody-mediated kidney transplant rejection (BORTEJECT Study): study protocol for a randomized controlled trial.
Eskandary F; Bond G; Schwaiger E; Kikic Z; Winzer C; Wahrmann M; Marinova L; Haslacher H; Regele H; Oberbauer R; Böhmig GA
Trials; 2014 Apr; 15():107. PubMed ID: 24708575
[TBL] [Abstract][Full Text] [Related]
3. Factors Predicting Risk for Antibody-mediated Rejection and Graft Loss in Highly Human Leukocyte Antigen Sensitized Patients Transplanted After Desensitization.
Vo AA; Sinha A; Haas M; Choi J; Mirocha J; Kahwaji J; Peng A; Villicana R; Jordan SC
Transplantation; 2015 Jul; 99(7):1423-30. PubMed ID: 25606792
[TBL] [Abstract][Full Text] [Related]
4. A Randomized Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection.
Eskandary F; Regele H; Baumann L; Bond G; Kozakowski N; Wahrmann M; Hidalgo LG; Haslacher H; Kaltenecker CC; Aretin MB; Oberbauer R; Posch M; Staudenherz A; Handisurya A; Reeve J; Halloran PF; Böhmig GA
J Am Soc Nephrol; 2018 Feb; 29(2):591-605. PubMed ID: 29242250
[TBL] [Abstract][Full Text] [Related]
5. Management of Plasma Cell-Rich Acute Rejection in Living-Related Kidney Transplant: Role of Proteasome Inhibitor.
Abbas K; Mubarak M; Zafar MN; Musharraf W; Imam M; Aziz T; Rizvi AH
Exp Clin Transplant; 2019 Feb; 17(1):42-46. PubMed ID: 29534661
[TBL] [Abstract][Full Text] [Related]
6. Late Antibody-Mediated Rejection in a Large Prospective Cross-Sectional Study of Kidney Allograft Recipients--Preliminary Results of the Screening Phase of the BORTEJECT Trial.
Eskandary F; Bond G; Regele H; Kozakowski N; Kikić Z; Wahrmann M; Haslacher H; Oberbauer R; Ramassar V; Halloran P; Böhmig GA
Clin Transpl; 2014; ():189-95. PubMed ID: 26281144
[TBL] [Abstract][Full Text] [Related]
7. Reducing Donor-specific Antibody During Acute Rejection Diminishes Long-term Renal Allograft Loss: Comparison of Early and Late Rejection.
Lichvar AB; Tremblay S; Leino AD; Shields AR; Cardi MA; Abu Jawdeh BG; Govil A; Kremer J; Cuffy M; Paterno F; Diwan T; Brailey P; Girnita A; Alloway RR; Woodle ES
Transplantation; 2020 Nov; 104(11):2403-2414. PubMed ID: 32000256
[TBL] [Abstract][Full Text] [Related]
8. B-cell activating factor, a predictor of antibody mediated rejection in kidney transplantation recipients.
Pongpirul W; Chancharoenthana W; Pongpirul K; Leelahavanichkul A; Kittikowit W; Jutivorakool K; Nonthasoot B; Avihingsanon Y; Eiam-Ong S; Praditpornsilpa K; Townamchai N
Nephrology (Carlton); 2018 Feb; 23(2):169-174. PubMed ID: 27888573
[TBL] [Abstract][Full Text] [Related]
9. Clazakizumab in late antibody-mediated rejection: study protocol of a randomized controlled pilot trial.
Eskandary F; Dürr M; Budde K; Doberer K; Reindl-Schwaighofer R; Waiser J; Wahrmann M; Regele H; Spittler A; Lachmann N; Firbas C; Mühlbacher J; Bond G; Halloran PF; Chong E; Jilma B; Böhmig GA
Trials; 2019 Jan; 20(1):37. PubMed ID: 30635033
[TBL] [Abstract][Full Text] [Related]
10. Preformed donor-specific antibodies and risk of antibody-mediated rejection in repeat renal transplantation.
Tsapepas DS; Vasilescu R; Tanriover B; Coppleson Y; Rekhtman Y; Hardy MA; Dube G; Crew RJ; Ratner LE; Cohen DJ; Mohan S
Transplantation; 2014 Mar; 97(6):642-7. PubMed ID: 24637863
[TBL] [Abstract][Full Text] [Related]
11. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
[TBL] [Abstract][Full Text] [Related]
12. Differential modulation of donor-specific antibodies after B-cell depleting therapies to cure chronic antibody mediated rejection.
Touzot M; Couvrat-Desvergnes G; Castagnet S; Cesbron A; Renaudin K; Cantarovich D; Giral M
Transplantation; 2015 Jan; 99(1):63-8. PubMed ID: 25029384
[TBL] [Abstract][Full Text] [Related]
13. The use of bortezomib as a rescue treatment for acute antibody-mediated rejection: report of three cases and review of literature.
Tzvetanov I; Spaggiari M; Joseph J; Jeon H; Thielke J; Oberholzer J; Benedetti E
Transplant Proc; 2012 Dec; 44(10):2971-5. PubMed ID: 23195008
[TBL] [Abstract][Full Text] [Related]
14. Microvascular inflammation in early protocol biopsies of renal allografts in cases of chronic active antibody-mediated rejection.
Tsuji T; Yanai M; Itami H; Ishii Y; Akimoto M; Fukuzawa N; Harada H; Fukasawa Y
Nephrology (Carlton); 2015 Jul; 20 Suppl 2():26-30. PubMed ID: 26031582
[TBL] [Abstract][Full Text] [Related]
15. Treatment of antibody-mediated rejection of kidney grafts with bortezomib and/or rituximab compared to standard regimen: experience of Slovene National Center.
Oblak T; Lindič J; Gubenšek J; Kveder R; Aleš Rigler A; Škoberne A; Večerić Haler Ž; Borštnar Š; Avguštin N; Ponikvar R; Mlinšek G; Ferluga D; Kojc N; Godnov U; Kovač D
Clin Nephrol; 2017 Supplement 1; 88(13):91-96. PubMed ID: 28664838
[TBL] [Abstract][Full Text] [Related]
16. Bortezomib as rescue therapy for antibody mediated rejection: a single-center experience.
Hardinger KL; Alford K; Murillo D
Clin Transpl; 2010; ():429-36. PubMed ID: 21696060
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib may stabilize pediatric renal transplant recipients with antibody-mediated rejection.
Pearl MH; Nayak AB; Ettenger RB; Puliyanda D; Palma Diaz MF; Zhang Q; Reed EF; Tsai EW
Pediatr Nephrol; 2016 Aug; 31(8):1341-8. PubMed ID: 27048228
[TBL] [Abstract][Full Text] [Related]
18. Treatment of acute antibody-mediated rejection using bortezomib: a case report.
Sin YH; Kim YJ; Oh JS; Lee JH; Kim SM; Kim JK
Nephrology (Carlton); 2015 Jul; 20 Suppl 2():86-9. PubMed ID: 26031595
[TBL] [Abstract][Full Text] [Related]
19. Bortezomib Eliminates Plasma Cells From a Renal Graft in Plasma Cell-Rich Acute Rejection.
Tasaki M; Saito K; Nakagawa Y; Ikeda M; Imai N; Ito Y; Sudo M; Ikezumi Y; Yamada T; Hasegawa H; Kobayashi T; Miura K; Narita I; Takahashi K; Tomita Y
Transplant Proc; 2019; 51(6):1732-1738. PubMed ID: 31301858
[TBL] [Abstract][Full Text] [Related]
20. Bortezomib for acute humoral rejection in two repeat transplant recipients.
Hardinger KL; Alford K; Murillo D
Clin Transpl; 2009; ():479-83. PubMed ID: 20524319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
